DST-0058

DST-0058 is an investigational **small molecule** drug being developed by DisperSol Technologies for **idiopathic pulmonary fibrosis**. Publicly available sources identify it only at a high level as a preclinical respiratory program and do not clearly disclose a validated molecular target, detailed mechanism of action, or commercial brand name. Available company and pipeline references indicate that it is part of DisperSol's development portfolio and that manufacturing support for the company's pipeline has involved Catalent, but the specific composition, formulation characteristics, and pharmacology of DST-0058 have not been publicly described in enough detail to support a more specific mechanistic annotation.